ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2012
Hepatitis B virus management to prevent reactivation after chemotherapy: a review.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.Hepatology (Baltimore, Md.) · 2017Pooled it
- Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.Annals of internal medicine · 2016Pooled it
- Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer.Alimentary pharmacology & therapeutics · 2026Article
- Cross-sectional study of hepatitis B virus infection in female breast cancer patients in China for the first time diagnosed.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- A cross-sectional survey of hepatitis B virus screening in patients who received immunosuppressive therapy for rheumatoid arthritis in Japan.Journal of pharmaceutical health care and sciences · 2024Article
- Change in Hepatitis B Surface Antibody Titers After Chemotherapy in Patients With Hematological Malignancies.Cureus · 2024Article
- Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy.World journal of clinical cases · 2021Review
- Risk factors forWorld journal of clinical cases · 2020Article
- High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan.International journal of clinical oncology · 2020Article
- Moderate Risk of Hepatitis B Virus Reactivation in HBsAgScientific reports · 2020Article
- Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand.Clinical and molecular hepatology · 2019Article
- Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System.Cancer medicine · 2018Article
- Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.Gastroenterology · 2017Review
- Infections in Cancer Patients with Solid Tumors: A Review.Infectious diseases and therapy · 2017Review
- The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours.The Journal of international medical research · 2016Article
- Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).Annals of hematology · 2015Review
- Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy.Clinical medicine (London, England) · 2014Article
- HBV treatment in a patient who will be receiving immunosuppressive therapy.Clinical liver disease · 2013Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
purposeReactivation of hepatitis B virus (HBV) infection after chemotherapy can lead to liver failure and death. Conflicting recommendations regarding HBV screening in cancer patients awaiting chemotherapy mean that some patients at risk for HBV reactivation are not being identified and treated with prophylactic antiviral therapy.
methodsWe performed a narrative review of the existing evidence regarding screening for and management of HBV infection among patients with cancer using Ovid Medline, PubMed, and the Cochrane Library.
resultsOur review showed inconsistencies in the definition and management strategies for HBV reactivation. The timeframe of reactivation is variable, and its molecular mechanisms are not clear. There are five effective antiviral agents that can be used as prophylaxis to prevent reactivation of HBV infection in cancer patients; however, the optimal drug and duration of therapy are unknown. Reactivation is more commonly reported in patients with hematologic malignancies receiving rituximab treatment, but reactivation can occur after other chemotherapies and in patients with solid tumors. Screening with all three screening tests-HBsAg, anti-HBc, and anti-HBs-allows the most thorough interpretation of a patient's serologic profile and assessment of reactivation risk; however, decision-making and cost-effectiveness studies are needed to determine optimal screening strategies.
conclusionsPrevention of reactivation of HBV infection depends on identification of patients at risk and initiation of antiviral prophylaxis, but data to guide screening and treatment strategies are lacking. Additional research is necessary to accurately define and predict reactivation, identify best antiviral treatment strategies, and identify cost-effective HBV screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.